Market Reports Center One Stop Market Reaserch Shop Asthma Therapeutics Market Share, Size, Emerging Trends and Growth, Analysis, Overview and Forecasts 2016-2020 Technavio Announces the Publication of its Research Report – Global Asthma Therapeutics Market 2016-2020 Technavio recognizes the following companies as the key players in the global asthma therapeutics market: AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GSK, Merck, Other Prominent Vendors in the market are: ALK-Abello, Amgen, Array BioPharma, Asmacure, Astellas Pharma, Axikin Pharmaceuticals, Chiesi Farmaceutici, Dynavax Technologies, Horizon Pharma, Hovione Scientia, Invion, Ivax, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma, Nycomed, Oxagen Limited, Palobiofarma, Pearl Therapeutics, Pharmaking, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, RSPR Pharma AB, SAMA Pharmaceuticals, Sanofi, Skyepharma, SolAeroMed, Stallergenes, Sterna Biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, Vectura, Verona Pharma, and Whanin Pharmaceutical. Browse full report with TOC@ https://marketreportscenter.com/reports/349432/global-asthmatherapeutics-market-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “One of the key trends for market growth will be innovative technologies for drug delivery. The industry's shift toward electronic systems technology like smart technology and EHR brings the level of perspective and accessibility across healthcare specialties. This reduces cost when administering expensive medications. Other recent advances include integration of add-on devices such as spacers, breath-actuated devices, and valved holding chambers in inhalers. Market Reports Center One Stop Market Reaserch Shop They help in reducing oropharyngeal deposition of inhaled corticosteroids and minimizes side effects. ” According to the report, one of the key drivers for market growth will be huge market potential for mAbs. mAbs will have a high uptake for the treatment of asthma, owing to the development of target specific drugs. mAbs blocking IgE are specifically approved for the treatment of allergic asthma. Asthmatic patients with phenotypes of severe refractory asthma will benefit from these mAbs. mAbs against immunoglobulin or specific cytokines, which are known to be important in the initiation or persistence of asthmatic inflammation are being developed. Xolair was the first mAb approved for the treatment of allergic asthma. Further, the report states that once of the challenges for the market will be increased preference for CAM. Individuals with allergic rhinitis and asthma tend to adopt alternative methods of treatment instead of pharmacologic treatment. According to a 2016 report, in the US above 20% of the population suffer from allergic diseases, including allergic asthma, allergic rhinitis, and atopic dermatitis, and more than 42% of the people use CAM for these conditions. The use of CAM for allergic conditions is higher in some European countries because of its better efficacy, favorable safety, and low cost of therapies. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/349432 About Asthma Therapeutics Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period. Technavio’ s analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be Market Reports Center One Stop Market Reaserch Shop launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To Get Discount On The Report @ https://marketreportscenter.com/request-discount/349432 Connect for more details: Sam Collins Market Reports Center 1-646-883-3044 (US) info@marketreportscenter.com
According to the report, one of the key drivers for market growth will be huge market potential for mAbs. mAbs will have a high uptake for the treatment of asthma, owing to the development of target specific drugs.
© Copyright 2024 Paperzz
